STAT

Is Trump’s memory declining? Simple tests during his physical could answer that question

Tests for memory and language use could be fairly reliable indicators of whether Trump is suffering from cognitive decline.

When President Trump has his physical exam on Friday, there is little chance he will repeat the same story within a span of 10 minutes or fail to recognize old friends, as the explosive new book “Fire and Fury” by Michael Wolff asserts he has done in the past.

But the mental deterioration that causes such memory lapses would be detectable on standard cognitive tests. The White House told reporters on Monday that psychiatric tests would not be conducted as part of the president’s physical, but did not explicitly rule out cognitive assessments.

The physical, which will take place at Walter Reed National Military Medical Center, comes amid an increasingly public debate about whether Trump is suffering cognitive decline precipitous enough to impair his capacity to carry out the work of the presidency.

Unlike tests for emotional instability, personality disorder, or other psychiatric disorders that some armchair

You're reading a preview, sign up to read more.

More from STAT

STAT4 min readSociety
Doctors Argue For Term Limits To Diversify Medical School Leadership
In a new paper, a group of doctors argues that medical schools should impose term limits on department chairs and deans to bring in more diverse perspectives.
STAT4 min readLeadership & Mentoring
Opinion: New Leaders Needed To Translate Discoveries Into Patient Care
To facilitate new discoveries, today's and tomorrow's leaders need to understand and navigate the languages and cultures of multiple sectors, from health care systems and academia to industry, finance, and…
STAT2 min readScience
New Vertex Cystic Fibrosis Drug Approved, Extending Treatments To 90% Of Patients
Vertex Pharmaceuticals on Monday won approval for its fourth treatment for cystic fibrosis, a combination drug that extends a new form of therapy to 90% of CF patients. The drug will be marketed as Trikafta. The list price is $311,000 per year — the